Abstracts Archive - Page 1674 of 2425 - ACR Meeting Abstracts

Abstract Number: 3031 • 2015 ACR/ARHP Annual Meeting
Dalazatide (ShK-186), a Kv1.3 Channel Inhibitor That Targets Effector Memory T Cells: Ex Vivo Studies in Pediatric Systemic Lupus Erythematosus
Megan Yuasa¹, David Peckham², Anne M. Stevens³, Shawn P. Iadonato² and Ernesto J. Muñoz-Elías⁴, ¹Seattle Children's Res Institute, Seattle Children's Research Institute, Seattle, WA, ²Kineta Inc, Seattle, WA, ³Seattle Children's Res Inst, Seattle Children's Hospital, Seattle, WA, ⁴Translational Immunology & Preclinical Development, Kineta, Inc., Seattle, WA
Background/Purpose: The voltage-gated potassium channel Kv1.3 is highly expressed on activated T effector memory cells (TEM), is essential for T cell activation, and thus is…
Abstract Number: 3032 • 2015 ACR/ARHP Annual Meeting
Role of Adenosine and Neutrophils in Inflammation Associated with Mutations in CECR1 Gene
Kyawt W. Shwin^1,2, Carmelo Carmona-Rivera³, Wanxia Tsai⁴, Chya-chia Richard Lee^5,6, Elaine Novakovich⁷, Deborah L. Stone⁸, Amanda K. Ombrello⁸, Raphaela Goldbach-Mansky⁹, Massimo Gadina¹⁰, Daniel Kastner¹¹, Ivona Aksentijevich^12,13, Mariana J. Kaplan⁷ and Peter C. Grayson^14,15, ¹NIAMS, National Institutes of Health, BETHESDA, MD, ²Translational Autoinflammatory Diseases Section, National Institutes of Health, Bethesda, MD, ³Systemic Autoimmunity Branch/ NIAMS, National Institutes of Health, Bethesda, MD, ⁴Translational Immunology, Office of Science and Technology, National Institutes of Health, Bethesda, MD, ⁵National Cancer Institute, National Institutes of Health, Bethesda, MD, ⁶Laboratory of Pathology, NCI, National Institutes of Health, BETHESDA, MD, ⁷Systemic Autoimmunity Branch, NIAMS, National Institutes of Health, Bethesda, MD, ⁸National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁹Translational Autoinflammatory Diseases Section, NIAMS, NIH, Bethesda, MD, ¹⁰Translational Immunology, Office of Science and Technology, NIAMS, National Institutes of Health, Bethesda, MD, ¹¹Inflammatory Disease Section, NHGRI, National Institutes of Health, Bethesda, MD, ¹²NIH/NHGRI, Metabolic, Cardiovascular, and Inflammatory Disease Genomics Branch, Bethesda, MD, ¹³Inflammatory Disease Section, National Human Genome Research Institute, Bethesda, MD, ¹⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁵NIAMS Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD
Background/Purpose: The phenotype of patients afflicted by deficiency of adenosine deaminase 2 (DADA2) due to mutations in CECR1encoding ADA2 protein shares many features with idiopathic…
Abstract Number: 3033 • 2015 ACR/ARHP Annual Meeting
Polyarteritis Nodosa and Cutaneous Arteritis: Are They Distinct Diseases?
Fatma Alibaz-Oner¹, Matthew J. Koster², Cynthia S. Crowson³, Ashima Makol², Steven R. Ytterberg², Eric L. Matteson² and Kenneth J. Warrington², ¹Department Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: Polyarteritis nodosa (PAN) is a rare systemic necrotizing vasculitis predominantly targeting medium-sized visceral arteries. Cutaneous arteritis (CA) is generally limited to the medium-sized vessels…
Abstract Number: 3034 • 2015 ACR/ARHP Annual Meeting
A Comparative Metabolomic Evaluation of Behcet’s Disease with Arthritis and Seronegative Arthritis Using Synovial Fluid
Joong Kyong Ahn¹, Sooah Kim², Jungyeon Kim², Jiwon Hwang³, Hyungjin Kim⁴, Hyemin Jeong⁵, Yeong Hee Eun⁶, Chan Hong Jeon⁷, Jaejoon Lee⁵, Eun-Mi Koh⁵, Kyoung Heon Kim² and Hoon-Suk Cha⁸, ¹Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Department of Biotechnology, Korea University Graduate School, Seoul, South Korea, ³Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Department of medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁵Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁶Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁷Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, South Korea, ⁸Division of Rheumatology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Behcet’s disease (BD) is a chronic, complex systemic vasculitis of unknown etiology characterized by orogenital ulcers, uveitis, and arthritis. Arthritis and arthralgias in BD…
Abstract Number: 3035 • 2015 ACR/ARHP Annual Meeting
HLA B51 and Possible Associated Autoimmune Disorders Other Than Behcets Disease: A Retrospective Cohort Study
Luis Salayandia¹, Wilmer Sibbitt Jr.¹, Arthur Bankhurst², Roderick Fields³, Gladys Cook⁴, Konstantin Konstantinov⁵ and Suzanne Emil¹, ¹Rheumatology, University of New Mexico, Albuquerque, NM, ²Rheum/ MSC 105550, University of NM Med Ctr, Albuquerque, NM, ³Rheumatology, University of New Mexico, Albquerque, NM, ⁴Rheumatology, UNM, Albuquerque, NM, ⁵1 University Of New Mexico, University of New Mexico, Albuquerque, NM
Background/Purpose: The diagnostic utility of HLA B51 in association with Behcet’s disease has been clearly identified; however the correlation of HLA B51 with other autoimmune…
Abstract Number: 3036 • 2015 ACR/ARHP Annual Meeting
The Association Between Behcet’s Disease, Myelodysplastic Syndrome and Trisomy 8
Won-Seok Lee¹, Yun Jung Choi², Myong-Joo Hong³, Chang-Hoon Lee⁴, Myeung Su Lee⁵, Young Sun Suh⁶, Sang-Il Lee⁷, Yong Gon Cho⁸ and Wan-Hee Yoo⁹, ¹Division of Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine of Chonbuk National University Hospital-Chonbuk National University, jeonju, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine of Chonbuk National University Hospital-Chonbuk National University, JeonJu, South Korea, ³Internal Medicine, Presbyterian Medical center, Jeonju, South Korea, ⁴Department of Internal Medicine, School of Medicine, Wonkwang University, Iksan, Chonbuk, South Korea, ⁵Internal Medicine, School of Medicine, Wonkwang University, Iksan, Chonbuk, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea, ⁷Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, South Korea, ⁸Department of Laboratory medicine, Chonbuk National University Medical School and Hospital, Jeonju, South Korea, ⁹Division of Rhuematology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine of Chonbuk National University Hospital-Chonbuk National University, Jeonju, South Korea
Background/Purpose: Behcet’s disease (BD) is a systemic vasculitis, whereas myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematologic disorders characterized by ineffective hematopoiesis. Some…
Abstract Number: 3037 • 2015 ACR/ARHP Annual Meeting
Serum Anti-Lysozyme Is Associated with Disease Activity of Behcet’s Disease
Jin Su Park¹, Mi-il Kang², You Jung Ha³, Yong-Beom Park⁴, Soo-Kon Lee⁵ and Sang-Won Lee⁶, ¹Department of Internal Medicine, NHIS Ilsan Hospital, Goyang-si Gyeounggi-do, South Korea, ²Department of Internal Medicine, Dankook University Hospital, Cheonan-si Chungcheongnam-do, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ⁴Yonsei University College of Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul, South Korea, ⁵Internal Medicine, Yonsei Univ College of Med, Seoul, South Korea, ⁶Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: To investigate the association between autoantibodies against non- myeloperoxidase (MPO) neutrophil granule antigens and activity of Behcet’s disease (BD). Methods: We consecutively enrolled 51…
Abstract Number: 3038 • 2015 ACR/ARHP Annual Meeting
Serum CXCL8, 10 and 12 Are Increased in Patients with Behcet’s Disease and CXCL10 Levels Are Correlated with Number of Erythema Nodosum
Sang Jin Lee^1,2, Hyun Jung Yoo³, Hyun Mi Kwon⁴, Jin Young Moon⁴, Jin Kyun Park⁵, Eun Young Lee⁵, Eun Bong Lee⁴ and Yeong Wook Song⁵, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ²Department of Molecular Medicine and Biopharmaceutical Sciences, BK21 plus Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy, Seoul National University, Seoul, South Korea, ³Department of Molecular Medicine and Biopharmaceutical Sciences, BK 21 plus Graduate School of Convergence Science and Technology, and College of Medicine or College of Parmarcy, Seoul National University, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea
Background/Purpose: Chemokines are multifunctional mediators that control leukocyte recruitment into the inflammatory sites and enhance immune responses. It remains to be investigated which chemokines are…
Abstract Number: 3039 • 2015 ACR/ARHP Annual Meeting
Possible Contribution of HLA-A0207, B5201 and IL-23 Receptor Polymorphism in Ocular Behçet Disease
Toshikatsu Kaburaki¹, Shinji Harihara², Rie Tanaka³, Hiromasa Sawamura⁴, Ai Nishi⁴, Atsushi Hatamochi⁵, Jun Shimizu⁶, Masumi Takeuchi⁷, Shoji Kuwata⁸, Hidetoshi Kawashima⁹ and Fujio Takeuchi¹⁰, ¹Ophthalmology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²Division of Anthropology, Department of Biological Science, The University of Tokyo Graduate School of Science, Tokyo, Japan, ³Department of Ophtalmology, The University of Tokyo Graduate School of Medicine,, Tokyo, Japan, ⁴Department of Ophtalmology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁵Department of Dermatology, Dokkyo Medical University, Tochigi, Japan, ⁶Department of Neurology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁷Teikyo University Support Center for Women Physicians and Researchers, Teikyo University School of Medicine, Tokyo, Japan, ⁸Third Department of Internal Medicine, Teikyo University Chiba Medical Center, Teikyo University School of Medicine, Chiba, Japan, ⁹Department of Ophthalmology, Jichi Medical University, Tochigi, Japan, ¹⁰Department of Allergy and Rheumatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Behçet's disease (BD) is known to be associated with HLA-B*51:01 and HLA- A*26:01 in many different ethnic groups. Recently, HLA-A*02:07, IL-10 and IL23R-IL12RB polymorphisms…
Abstract Number: 3040 • 2015 ACR/ARHP Annual Meeting
Predictive Factors of Long-Term Clinical Outcome in Patients with Ocular Involvement Secondary to Behcet’s Syndrome
Rosaria Talarico¹, Michele Figus², Anna d'Ascanio¹, Rossella Neri¹, Chiara Baldini¹, Chiara Tani³ and Marta Mosca¹, ¹Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ²Department of Surgical, Medical, Molecular Pathology and Emergency, University of Pisa, Pisa, Italy, ³University of Pisa, Pisa, Italy
Background/Purpose: Behçet's syndrome (BS) is a multisystemic, chronic relapsing inflammatory disease classified among the vasculitis. Eye involvement represent one of the most serious manifestation of…
Abstract Number: 3041 • 2015 ACR/ARHP Annual Meeting
Long Term Biological Therapy in Uveitis Refractory Due to Behçet’s Disease. Multicenter Study of 165 Patients.
Montserrat Santos-Gómez¹, Vanesa Calvo-Río¹, Ricardo Blanco¹, Emma Beltran², Juan Sánchez Bursón Sr.³, Marina Mesquida⁴, Alfredo Adan⁴, M. Victoria Hernández⁵, F.Javier López-Longo⁶, Marisa Hernandez Grafella⁷, Elia Valls Pascual⁸, Lucía Martinez-Costa⁹, Agusti Sellas-Fernandez¹⁰, Miguel Cordero¹¹, Manuel Díaz-Llopis¹², Roberto Gallego¹³, Jose L. García Serrano¹⁴, JL Callejas Rubio¹⁵, Norberto Ortego-Centeno¹⁶, Jose M Herreras¹⁷, Alejandro Fonollosa¹⁸, Angel M. Garcia-Aparicio¹⁹, Olga Maiz Alonso²⁰, Ana Blanco²¹, Ignacio Torre²², Cruz Fernández- Espartero²³, Vega Jovani²⁴, Diana Peiteado²⁵, David Diaz Valle²⁶, Esperanza Pato²⁶, Juan Cruz²⁷, Carlos Férnandez Cid²⁸, Elena Aurrecoechea²⁹, Miriam García-Arias³⁰, Miguel Angel Caracuel-Ruiz³¹, Carlos Alberto Montilla Morales³², Antonio Atanes-Sandoval³³, Félix Francisco³⁴, Santos Insua³⁵, Senen González-Suárez³⁶, Amalia Sánchez-Andrade³⁷, Fernando Gamero³⁸, Luis Francisco Linares³⁹, Fredeswinda Romero⁴⁰, A. Javier García-González⁴¹, Raquel Almodóvar González⁴², Enrique Minguez⁴³, Carmen Carrasco Cubero⁴⁴, Alejandro Olivé⁴⁵, Julio Vázquez⁴⁶, Oscar Ruiz Moreno⁴⁷, Fernando Jiménez-Zorzo⁴⁸, Javier Manero⁴⁸, Santiago MuÑoz Fernandez⁴⁹, Cristina Fernández-Carballido⁵⁰, Esteban Rubio Romero⁵¹, Fred Antón Pagés⁵², Javier Toyos-Saenz de Miera⁵³, Myriam Gandía⁵⁴, Carmen Gonzalez-Vela⁵⁵, Enrique Raya⁵⁶, Natalia Palmou¹, Leyre Riancho-Zarrabeitia¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Rheumatology, Hospital General Universitario de Valencia, Valencia, Spain, ³Rheumatology, Hospital de Valme., Sevilla, Spain, ⁴Ophthalmology, Hospital Clinic, Barcelona, Spain, ⁵Arthritis Unit, Rheumatology, Hospital Clinic, Barcelona, Spain, ⁶Hospital Gregorio Marañón, Madrid, Spain, ⁷Ophthalmology., Hospital General Universitario de Valencia, Valencia, Spain, ⁸Rheumatology, Hospital Universitario Dr Peset, Valencia, Spain, ⁹Ophthalmology, Hospital Universitario Dr Peset, Valencia, Spain, ¹⁰Rheumatology, Hospital Universitario Valle Hebron, Barcelona, Spain, ¹¹Ophthalmology, Hospital de León, León, Spain, ¹²Hospital Universitario La Fe, Valencia, Spain, ¹³Ophthalmology, Hospital Universitario La Fe, Valencia, Spain, ¹⁴Ophthalmology, Hospital Universitario San Cecilio, Granada, Spain, ¹⁵Hospital Universitario San Cecilio, Granada, Spain, ¹⁶Systemic Autoimmune Diseases Unit, Hospital Universitario San Cecilio, Granada, Spain, ¹⁷Ophthalmology, Hospital Universitario, IOBA, Valladolid, Spain, ¹⁸Ophtalmology, Hospital de Cruces, Bilbao, Spain, ¹⁹Rheumatology, Hospital Virgen de la Salud, Toledo, Spain, ²⁰Rheumatology, Donostia University Hospital, Donostia, Spain, ²¹Ophthalmology, Donostia University Hospital, Donostia, Spain, ²²Rheumatology, Hospital de Basurto, Bilbao, Spain, ²³Rheumatology, Hospital La Zarzuela, Madrid, Spain, ²⁴Rheumatology, Hospital General de Alicante, Alicante, Spain, ²⁵Rheumatology, Hospital La Paz, Madrid, Spain, ²⁶Hospital Clínico San Carlos, Madrid, Spain, ²⁷Rheumatology, Hospital de Pontevedra, Pontevedra, Spain, ²⁸Ophthalmology, Hospital de Pontevedra, Pontevedra, Spain, ²⁹Rheumatology, Hospital de Sierrallana, Torrelavega, Spain, ³⁰Rheumatology, Hospital La Princesa, Madrid, Spain, ³¹Plaza Cruz Roja, 1, Hospital Reina Sofia, Córdoba, Spain, ³²Rheumatology, Hospital Universitario de Salamanca, Salamanca, Spain, ³³Rheumatology, Complejo Hospitalario Universitario de La Coruña, La Coruña, Spain, ³⁴Rheumatology, Hospital Doctor Negrín, Las Palmas de Gran Canaria, Spain, ³⁵Rheumatology, Hospital Universitario Santiago de Compostela, La Coruña, Spain, ³⁶Rheumatology, Hospital de Cabueñes, Gijón, Spain, ³⁷Hospital Lucus Augusti, Lugo, Spain, ³⁸Rheumatology, Hospital San Pedro Alcántara, Cáceres, Spain, ³⁹Rheumatology, Hospital Virgen de la Arrixaca, Murcia, Spain, ⁴⁰Section for Autoimmune Diseases, Rheumatology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ⁴¹Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴²Rheumatology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain, ⁴³Ophthalmology., Hospital Clínico de Zaragoza, Zaragoza, Spain, ⁴⁴Rheumatology, Hospital de Mérida, Mérida, Spain, ⁴⁵Hospital Germans Trias i Pujol, Badalona, Spain, ⁴⁶Rheumatology., Hospital de Ferrol, La Coruña, Spain, ⁴⁷Ophthalmology and Rheumatology., Hospital Miguel Servet, Zaragoza, Spain, ⁴⁸Ophthalmology and Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ⁴⁹Rheumatology, Hospital Infanta Sofía, Madrid, Spain, ⁵⁰Rheumatology, Hospital General Universitario de Elda, Elda (Alicante), Spain, ⁵¹Rheumatology Department,, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁵²Rheumatology, Hospital de Palencia, Palencia, Spain, ⁵³Rheumatology, Hospital Virgen de la Macarena, Seville, Spain, ⁵⁴Department of Autoimmune Diseases, IDIBAPS, Hospital Clínic, Barcelona, Spain, ⁵⁵Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁵⁶Rheumatology, Hospital Universitario San Cecilio, Granada, Spain
Background/Purpose: Conventional management of uveitis due to Behçet’s disease (UBD) consists on conventional immunosuppressive drugs. However, UBD is often refractory requiring more intensive therapy.Our aim was…
Abstract Number: 3042 • 2015 ACR/ARHP Annual Meeting
Tocilizumab in Refractory Uveitis Associated with Behçet’s Disease. Multicenter Study of 7 Patients.
Montserrat Santos-Gómez¹, Vanesa Calvo-Río¹, Ricardo Blanco¹, Emma Beltran², Antonio Atanes-Sandoval³, Enar Pons⁴, Javier Loricera¹, Carmen Gonzalez-Vela⁵, Leyre Riancho-Zarrabeitia¹, Natalia Palmou¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Rheumatology, Hospital General Universitario de Valencia, Valencia, Spain, ³Rheumatology, Complejo Hospitalario Universitario de La Coruña, La Coruña, Spain, ⁴Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁵Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: Treatment recommended in severe and/or refractory uveitis of Behçet disease is anti-TNF-α therapy, usually infliximab (IFX) or adalimumab (ADA) (Levy-Clarke et al Ophthalmology 2014;121:785-796).…
Abstract Number: 3043 • 2015 ACR/ARHP Annual Meeting
IL-17 Expression By Lymphocytes Is Higher in Behcet’s Disease Compared to Takayasu Arteritis
Ali Ugur Unal¹, Rabia Deniz², Aysin Tulunay Virlan³, Filiz Ture Ozdemir³, Imren Aydin Tatli³, Gulsen Ozen¹, Fatma Alibaz-Oner⁴, Gonca Mumcu⁵, Tulin Ergun⁶ and Haner Direskeneli¹, ¹Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ²Marmara University Faculty of Medicine, Istanbul, Turkey, ³Department of Immunology, Marmara University Faculty of Medicine, Istanbul, Turkey, ⁴Department Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ⁵Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ⁶Dermatology, Marmara University Faculty of Medicine, Dermatology, Istanbul, Turkey
Background/Purpose: Interleukin-17 (IL-17) has been associated with the pathogenesis of various inflammatory diseases. The aim of our study was to investigate the expression of Th17-related…
Abstract Number: 3044 • 2015 ACR/ARHP Annual Meeting
Microparticles (MPs) Derived from Cell Plasma Membranes Are Increased in Behcet’s Syndrome (BS) and a Low Ratio of Tissue Factor Pathway Inhibitor Positive Mps to Tissue Factor Positive Mps (TFPI/TF) Is Associated with Thrombosis
Emon Khan¹, Nicola Ambrose¹, Miles Stanford², Michael A. Laffan³ and Dorian O. Haskard⁴, ¹Department of Vascular Sciences, National Heart and Lung Institute, Imperial College, London, United Kingdom, ²Ophthalmology, Guy's and St. Thomas' Hospital, London, United Kingdom, ³Department of Haemostasis and Thrombosis, Imperial College, London, United Kingdom, ⁴Rheumatology, Imperial College, London, United Kingdom
Background/Purpose: Thrombosis occurs in around 20% of Behçet's Syndrome (BS) patients and causes substantial morbidity. There is a clear need for better biomarkers of thrombotic…
Abstract Number: 3045 • 2015 ACR/ARHP Annual Meeting
Anti-Alpha-Enolase Antibodies in Behçet’s Disease: A Marker of Articular Disease Activity?
Leandro L. Prado, Celio R. Gonçalves, Vilma S. T. Viana, Eloisa Bonfá and Carla G.S. Saad, Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Diagnosis of Behçet´s disease (BD) is challenging because is based solely on clinical features. Articular involvement in this disease may mimic other diagnosis such…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].